ATE508190T1 - Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien - Google Patents
Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentienInfo
- Publication number
- ATE508190T1 ATE508190T1 AT05727680T AT05727680T ATE508190T1 AT E508190 T1 ATE508190 T1 AT E508190T1 AT 05727680 T AT05727680 T AT 05727680T AT 05727680 T AT05727680 T AT 05727680T AT E508190 T1 ATE508190 T1 AT E508190T1
- Authority
- AT
- Austria
- Prior art keywords
- expression cassettes
- simultaneous delivery
- rnai agent
- multiple promotor
- promotor expression
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title abstract 2
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55050404P | 2004-03-05 | 2004-03-05 | |
| US55392004P | 2004-03-17 | 2004-03-17 | |
| PCT/US2005/007447 WO2005087926A2 (en) | 2004-03-05 | 2005-03-04 | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE508190T1 true ATE508190T1 (de) | 2011-05-15 |
Family
ID=34963938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05727680T ATE508190T1 (de) | 2004-03-05 | 2005-03-04 | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7727970B2 (de) |
| EP (2) | EP1725660B1 (de) |
| JP (1) | JP4763681B2 (de) |
| KR (2) | KR101337579B1 (de) |
| CN (1) | CN103060324B (de) |
| AT (1) | ATE508190T1 (de) |
| AU (1) | AU2005222084B2 (de) |
| CA (1) | CA2558771C (de) |
| DE (1) | DE602005027820D1 (de) |
| DK (1) | DK1725660T3 (de) |
| IL (1) | IL177862A (de) |
| NZ (1) | NZ550284A (de) |
| WO (1) | WO2005087926A2 (de) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005087926A2 (en) * | 2004-03-05 | 2005-09-22 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| EP1797185B1 (de) * | 2004-09-24 | 2011-04-13 | Alnylam Pharmaceuticals, Inc. | Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai |
| JP2008520243A (ja) * | 2004-11-18 | 2008-06-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 腫瘍を阻害するための多シストロン性ｓｉＲＮＡコンストラクト |
| WO2006084209A2 (en) * | 2005-02-03 | 2006-08-10 | Benitec, Inc. | Rnai expression constructs |
| US20070081982A1 (en) * | 2005-04-28 | 2007-04-12 | Elisabeth Evertsz | Multiple RNAi expression cassettes for simultaneous delivery of RNAi agents related to heterozygotic expression patterns |
| US7452696B2 (en) * | 2006-10-27 | 2008-11-18 | National Taiwan University | Recombinant plasmid and method for expressing hepatitis B viral antigens and virions in vivo |
| US8114982B2 (en) * | 2006-12-06 | 2012-02-14 | Albert Einstein College Of Medicine Of Yeshiva University | Multi-microRNA methods and compositions |
| WO2008134720A2 (en) * | 2007-04-30 | 2008-11-06 | Medtronic, Inc. | Inert dna sequences for efficient viral packaging and methods of use |
| WO2009002918A2 (en) | 2007-06-22 | 2008-12-31 | Nucleonics, Inc. | Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| US20100042072A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| US20100041133A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| US20100040546A1 (en) * | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| US20120034156A1 (en) * | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| CA2833905C (en) * | 2010-04-23 | 2019-09-10 | University Of Massachusetts | Multicistronic expression constructs |
| DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
| EP2561075B1 (de) | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-basierte behandlung von cholesterinerkrankungen |
| PT3124610T (pt) | 2010-10-28 | 2019-06-14 | Benitec Biopharma Ltd | Tratamento do vhb |
| KR101554678B1 (ko) * | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| KR20150103280A (ko) | 2013-01-08 | 2015-09-09 | 베니텍 바이오파마 리미티드 | 연령-관련 황반 변성 치료 |
| AU2015231294B2 (en) | 2014-03-18 | 2020-10-29 | University Of Massachusetts | rAAV-based compositions and methods for treating amyotrophic lateral sclerosis |
| GB201405834D0 (en) * | 2014-04-01 | 2014-05-14 | Univ London Queen Mary | Oncolytic virus |
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
| EP3795580A1 (de) | 2014-10-03 | 2021-03-24 | University of Massachusetts | Hocheffiziente bibliotheksidentifizierte aav-vektoren |
| WO2016065001A1 (en) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
| MX2017006217A (es) | 2014-11-14 | 2018-05-02 | Voyager Therapeutics Inc | Polinucleotidos moduladores. |
| RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
| US10517898B2 (en) | 2014-11-20 | 2019-12-31 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
| US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
| CA3021949C (en) | 2015-04-24 | 2023-10-17 | University Of Massachusetts | Modified aav constructs and uses thereof |
| WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
| US11426469B2 (en) | 2015-10-22 | 2022-08-30 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| CN108699556B (zh) | 2015-11-16 | 2023-02-17 | 奥利克斯医药有限公司 | 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性 |
| CA3022874A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1 |
| EP3411059A4 (de) | 2016-02-02 | 2019-10-16 | University Of Massachusetts | Verfahren zur erhöhung der wirksamkeit der systemischen abgabe von avv-genen an das zentrale nervensystem |
| EP3413928B1 (de) | 2016-02-12 | 2022-04-20 | University of Massachusetts | Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut |
| US11207426B2 (en) | 2016-04-05 | 2021-12-28 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
| WO2017181105A1 (en) | 2016-04-15 | 2017-10-19 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2017218852A1 (en) | 2016-06-15 | 2017-12-21 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
| WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
| US11202818B2 (en) | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| WO2018112365A2 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii |
| WO2018112360A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| WO2018112364A1 (en) | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| US20190314427A1 (en) | 2016-12-16 | 2019-10-17 | Evelo Biosciences, Inc. | Methods of treating cancer using parabacteroides |
| US20190365830A1 (en) | 2017-01-18 | 2019-12-05 | Evelo Biosciences, Inc. | Methods of treating cancer |
| US20200121739A1 (en) | 2017-01-18 | 2020-04-23 | Evelo Biosciences, Inc. | Bacteria for treating cancer |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP3622073A4 (de) | 2017-05-09 | 2021-01-06 | University of Massachusetts | Verfahren zur behandlung von amyotropher lateralsklerose (als) |
| WO2019046401A1 (en) | 2017-08-29 | 2019-03-07 | Evelo Biosciences, Inc. | TREATMENT OF CANCER USING BLAUTIA STRAIN |
| JP7397488B2 (ja) | 2017-09-22 | 2023-12-13 | ユニバーシティ オブ マサチューセッツ | Ｓｏｄ１二重発現ベクターおよびその使用 |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| CN111479924B (zh) | 2017-10-16 | 2024-06-14 | 沃雅戈治疗公司 | 肌萎缩性侧索硬化症(als)的治疗 |
| WO2019169160A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using ruminococcus gnavus |
| WO2019169168A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using agathobaculum |
| WO2019169138A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using paraclostridium benzoelyticum |
| WO2019169143A1 (en) | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using turicibacter sanguinis |
| WO2019178057A1 (en) | 2018-03-12 | 2019-09-19 | Evelo Biosciences, Inc. | Methods of treating cancer using burkholderia |
| WO2019217522A1 (en) * | 2018-05-08 | 2019-11-14 | Mayo Foundation For Medical Education And Research | Methods for treating ovarian cancer |
| US12163129B2 (en) | 2018-06-08 | 2024-12-10 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| GB201816547D0 (en) | 2018-10-10 | 2018-11-28 | Univ London Queen Mary | Oncolytic virus for the treatment of cancer |
| WO2020172229A1 (en) * | 2019-02-19 | 2020-08-27 | Board Of Regents, The University Of Texas System | Genetic targeting of cellular or neuronal sub-populations |
| BR112021017864A2 (pt) | 2019-03-12 | 2021-12-07 | Harvard College | Métodos e composições para tratamento do câncer |
| WO2020206385A1 (en) | 2019-04-05 | 2020-10-08 | Earli Inc. | Improved methods and compositions for synthetic biomarkers |
| US20220226269A1 (en) | 2019-06-12 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| WO2021022110A1 (en) | 2019-08-01 | 2021-02-04 | Evelo Biosciences, Inc. | Inducing immune effects using bacteria of the genus bifidobacterium |
| US20230070129A1 (en) | 2020-01-06 | 2023-03-09 | Seasun Therapeutics | Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient |
| JP2023515671A (ja) | 2020-03-04 | 2023-04-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫療法に対する腫瘍細胞の感作のための方法及び組成物 |
| WO2021188534A1 (en) * | 2020-03-16 | 2021-09-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for improving heart function and treating heart failure |
| WO2021242826A1 (en) | 2020-05-27 | 2021-12-02 | The Regents Of The University Of California | Compositions and methods for transdifferentiating cells |
| WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
| AU2021344422A1 (en) | 2020-09-16 | 2023-05-04 | Gordon J. Freeman | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| CN119137278A (zh) * | 2022-03-24 | 2024-12-13 | 细胞和大脑有限公司 | 新型重组载体及其用途 |
| JP2025510135A (ja) * | 2022-03-24 | 2025-04-14 | セル・アンド・ブレイン・カンパニー・リミテッド | 新規組換えベクターおよびその用途 |
| WO2025038750A2 (en) | 2023-08-14 | 2025-02-20 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194140B1 (en) * | 1990-04-04 | 2001-02-27 | Chiron Corporation | HCV NS3 protein fragments having helicase activity and improved solubility |
| DK0527788T3 (da) * | 1990-04-04 | 2004-09-06 | Chiron Corp | Hepatitis C virus protease |
| WO2002081494A1 (en) * | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| US6127116A (en) | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| KR20010042069A (ko) | 1998-03-20 | 2001-05-25 | 베니텍 오스트레일리아 리미티드 | 유전자 발현 조절방법 |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| EP1272630A2 (de) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methoden und zusammensetzungen zur interferenz durch rna |
| AU2001254563A1 (en) | 2000-04-21 | 2001-11-12 | Boehringer Ingelheim (Canada) Ltd. | Internal de novo initiation sites of the hcv ns5b polymerase and use thereof |
| US6693701B2 (en) * | 2001-05-29 | 2004-02-17 | Ibsen Photonics A/S | Method and apparatus for diffractive transfer of a mask grating |
| AUPR644301A0 (en) * | 2001-07-17 | 2001-08-09 | Unisearch Limited | Method and composition for treatment of cancer |
| WO2003016572A1 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Oligonucleotide therapeutics for treating hepatitis c virus infections |
| EP1424895B1 (de) | 2001-09-13 | 2009-08-12 | California Institute Of Technology | Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle |
| WO2003046186A1 (fr) * | 2001-11-28 | 2003-06-05 | Toudai Tlo, Ltd. | Systeme d'expression d'arnsi et procede de production de cellule knockdown a gene fonctionnel ou analogue utilisant ce systeme |
| ATE519774T1 (de) * | 2002-02-20 | 2011-08-15 | Sirna Therapeutics Inc | Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina) |
| EP1490489B1 (de) * | 2002-03-14 | 2010-06-02 | Commonwealth Scientific and Industrial Research Organisation | Verfahren und mittel zur überwachung und modulation des gen-silencing |
| DE10212892A1 (de) * | 2002-03-20 | 2003-10-09 | Basf Plant Science Gmbh | Konstrukte und Verfahren zur Regulation der Genexpression |
| WO2003079757A2 (en) | 2002-03-20 | 2003-10-02 | Massachusetts Institute Of Technology | Hiv therapeutic |
| US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| US8211455B2 (en) * | 2002-06-19 | 2012-07-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
| AU2003261231A1 (en) * | 2002-07-26 | 2004-02-16 | Chiron Corporation | Modified small interfering rna molecules and methods of use |
| WO2004020605A2 (en) | 2002-08-29 | 2004-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Circular nucleic acid vectors, and methods for making and using the same |
| JP4545091B2 (ja) * | 2003-01-24 | 2010-09-15 | 財団法人 東京都医学研究機構 | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
| CN1276976C (zh) | 2003-10-30 | 2006-09-27 | 封江南 | 单一载体编码多个发夹结构小干扰性rna表达系统及其构建方法 |
| ES2366126T3 (es) * | 2004-03-05 | 2011-10-17 | Benitec, Inc. | CASSETTE DE EXPRESIÓN DE PROMOTOR MÚLTIPLE PARA EL SUMINISTRO SIMULTÁNEO DE AGENTES ARNi. |
| WO2005087926A2 (en) | 2004-03-05 | 2005-09-22 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
-
2005
- 2005-03-04 WO PCT/US2005/007447 patent/WO2005087926A2/en not_active Ceased
- 2005-03-04 JP JP2007502094A patent/JP4763681B2/ja not_active Expired - Fee Related
- 2005-03-04 US US11/072,592 patent/US7727970B2/en not_active Expired - Fee Related
- 2005-03-04 KR KR1020127000533A patent/KR101337579B1/ko not_active Expired - Fee Related
- 2005-03-04 EP EP05727680A patent/EP1725660B1/de not_active Expired - Lifetime
- 2005-03-04 CN CN201210556628.0A patent/CN103060324B/zh not_active Expired - Fee Related
- 2005-03-04 NZ NZ550284A patent/NZ550284A/en not_active IP Right Cessation
- 2005-03-04 AU AU2005222084A patent/AU2005222084B2/en not_active Ceased
- 2005-03-04 KR KR1020067020986A patent/KR101246862B1/ko not_active Expired - Fee Related
- 2005-03-04 DK DK05727680.0T patent/DK1725660T3/da active
- 2005-03-04 CA CA2558771A patent/CA2558771C/en not_active Expired - Fee Related
- 2005-03-04 AT AT05727680T patent/ATE508190T1/de not_active IP Right Cessation
- 2005-03-04 DE DE602005027820T patent/DE602005027820D1/de not_active Expired - Lifetime
- 2005-03-04 EP EP11161216.4A patent/EP2363483A3/de not_active Withdrawn
-
2006
- 2006-09-03 IL IL177862A patent/IL177862A/en not_active IP Right Cessation
-
2010
- 2010-03-12 US US12/723,466 patent/US8283461B2/en not_active Expired - Fee Related
-
2012
- 2012-09-26 US US13/627,644 patent/US8691967B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103060324A (zh) | 2013-04-24 |
| KR101337579B1 (ko) | 2013-12-06 |
| AU2005222084B2 (en) | 2010-04-22 |
| KR101246862B1 (ko) | 2013-03-27 |
| KR20070063470A (ko) | 2007-06-19 |
| CA2558771A1 (en) | 2005-09-22 |
| KR20120008094A (ko) | 2012-01-25 |
| US20110003378A1 (en) | 2011-01-06 |
| WO2005087926A3 (en) | 2006-03-16 |
| EP1725660A2 (de) | 2006-11-29 |
| EP2363483A3 (de) | 2014-07-16 |
| EP2363483A2 (de) | 2011-09-07 |
| CA2558771C (en) | 2013-01-08 |
| US8691967B2 (en) | 2014-04-08 |
| US20130171726A1 (en) | 2013-07-04 |
| US8283461B2 (en) | 2012-10-09 |
| JP2007527244A (ja) | 2007-09-27 |
| IL177862A0 (en) | 2006-12-31 |
| US20050197313A1 (en) | 2005-09-08 |
| NZ550284A (en) | 2009-04-30 |
| DK1725660T3 (da) | 2011-08-29 |
| DE602005027820D1 (de) | 2011-06-16 |
| IL177862A (en) | 2014-05-28 |
| CN103060324B (zh) | 2015-04-01 |
| EP1725660B1 (de) | 2011-05-04 |
| AU2005222084A1 (en) | 2005-09-22 |
| US7727970B2 (en) | 2010-06-01 |
| JP4763681B2 (ja) | 2011-08-31 |
| WO2005087926A2 (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE508190T1 (de) | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien | |
| CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
| UY29246A1 (es) | Nuevos compuestos | |
| TW200806317A (en) | Methods for reducing protein aggregation | |
| CR20110477A (es) | Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38 | |
| EA201001628A1 (ru) | Модифицированные полипептиды фактора vii и их применение | |
| NO20071127L (no) | Triazoloftalaziner | |
| CR20110230A (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| HRP20150828T8 (hr) | Kompozicije i postupci in vitro i in vivo ciljanog oslobađanja lijeka u stanicama sisavaca, preko intaktnih mini-stanica izvedenih iz bakterija | |
| EP3118218A3 (de) | Fusionsproteine zur verabreichung in die blut-hirn-schranke | |
| EP2061907A4 (de) | Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| CY1116482T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια ογκων, ινωσης, και πνευμονικης κυψελιδικης πρωτεϊνωσης | |
| ATE375518T1 (de) | Diagnoseverfahren für erkrankungen unter verwendung von copeptin | |
| DK1874341T3 (da) | Erythrocytter, der indeholder arginin deiminase | |
| CY1119509T1 (el) | Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης | |
| DE602004011334D1 (de) | Rüttler für Zellkulturklimaschrank | |
| EP2195331A4 (de) | Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren | |
| BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
| EA201071031A1 (ru) | Носители никорандила с повышенной стабильностью | |
| CL2009000257A1 (es) | Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico. | |
| FR2872431B1 (fr) | Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire | |
| DOP2007000020A (es) | Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias | |
| EA200801297A1 (ru) | Способ снижения уровня постпрандиальной глюкозы | |
| EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |